

Slides for RAC Meeting

Sept 17, 2007

Targeted Genetics Corp
Product and Patient Sample Testing

Additional Testing on Subject 1209

Samples Available at TGC

Histoplasma Antigen testing
MiraVista Laboratories, ELISA Assay

Study Visit	Sample Type	Histoplasma Antigen (ng/mL)	Interpretation
A12 (5/29/07)	serum	None detected	Negative
B0 (7/2/07)	serum	< 0.6 ng/mL	Positive, low

Additional Testing on Subject 1209

Samples Available at TGC

HSV-1 by DNA-PCR

Mayo Clinical Diagnostic Lab

Study Visit	Sample Type	HSV DNA Result
A0 (2/26/07)	Serum	negative
A4 (3/28/07)	Serum	negative
B0 (7/2/07)	Serum	negative
B0 (7/2/07)	Synovial fluid	negative

Recent Repeat Tests for tgAAC94 Drug Product Lot

- Safety and Purity

- Sterility performed by Bioreliance
 - Pass (verbal report)
- Histoplasma capsulatum by culture (clinical dose) performed by EMSL
 - Data pending (4-6 week assay, results expected mid Oct. 2007)
- HSV-1 by infectivity (clinical dose) performed by Bioreliance
 - Negative (in vitro assay, preliminary unaudited results from day 14)
- Residual infectious Ad5 (clinical dose) performed by TGC
 - Negative
- huTNFR:Fc protein in drug product vials performed by Biomonitor
 - No functional TNFalpha binding activity (no functional Etanercept) could be detected [preliminary unaudited results reported by Biomonitor]